Tadalafil vs Udenafil

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Pulmonary Arterial Hypertension

Shared mechanism: PDE5 · full Pulmonary Arterial Hypertension pipeline

Tadalafil · Adcirca

Marketed by Eli Lilly and partners

Approved in Pulmonary Arterial Hypertensionsmall molecule
Weak signal

NCT00549302 · Phase 3 · completed

This trial continued participants who had already been randomized in an earlier placebo-controlled study rather than randomizing a new population, and its own primary outcome was a pooled safety tally without a placebo comparator, so it provides supportive long-term evidence rather than a fresh controlled demonstration of efficacy. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Adverse Events (AEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: May 2028 · NCT06968962 (registry estimate)

Reported efficacy

Period 1: Change From Baseline to Week 24 in a 6 Minute Walk (MW) Distance in Meters (Baseline, Week 24): 6-minute walk distance change from baseline at Week 24: LS mean 60.48 m (SE 20.41) tadalafil vs 36.60 m (SE 20.78) placebo; placebo-adjusted mean difference 23.88 m (SD 29.11) (missed)

Result source: NCT01824290

Udenafil · Zydena

Marketed by Dong-A ST and partners

Phase 2/3 in Pulmonary Arterial Hypertensionsmall molecule
Weak signal

NCT02304198 · Phase 2/3 · completed

The study was an open-label, single-group continuation of the randomized DA8159_PAH_II trial, with 59 participants and no concurrent placebo or active comparator. Its registered primary outcome on ClinicalTrials.gov is "Safety (Adverse Events, Physical Examination, Vital Sign, Electrocardiography, Laboratory test, etc)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

Results for Pulmonary Arterial Hypertension

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Udenafil: no structured comparison results are available for Pulmonary Arterial Hypertension.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tadalafil

PAH Deterioration Free 96% (n=294) @ 16wk40 mg
absolute value · percentage points
No placebo or comparator arm
NCT00549302 · Phase 3
show 7 more results
90% (n=294) @ 28wk40 mg
NCT00549302 · Phase 3
88% (n=294) @ 40wk40 mg
NCT00549302 · Phase 3
85% (n=294) @ 52wk40 mg
NCT00549302 · Phase 3
95% (n=63) @ 16wk20 mg
NCT00549302 · Phase 3
88% (n=63) @ 28wk20 mg
NCT00549302 · Phase 3
81% (n=63) @ 40wk20 mg
NCT00549302 · Phase 3
81% (n=63) @ 52wk20 mg
NCT00549302 · Phase 3
RV Mass Change 28 g @ 36wk
absolute change · g
No placebo or comparator arm
NCT01042158 · Phase 4 · registry result, not featured evidence · combination
PVR 3.1 Wood units @ 36wk
absolute change · Wood units
No placebo or comparator arm
NCT01042158 · Phase 4 · registry result, not featured evidence · combination
TAPSE Change 1.65 cm @ 36wk
absolute change · cm
No placebo or comparator arm
NCT01042158 · Phase 4 · registry result, not featured evidence · combination
6MWD - Change 395 m @ 36wk
absolute change · m
No placebo or comparator arm
NCT01042158 · Phase 4 · registry result, not featured evidence · combination
show 2 more results
48.98 m @ 24wk
NCT01178073 · Phase 3 · registry result, not featured evidence · combination
22.7 m @ 24wk
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy
Clinical Failure 18.2% (n=253) @ 87wk
event rate · % of participants
No placebo or comparator arm
First adjudicated clinical failure event
NCT01178073 · Phase 3 · registry result, not featured evidence · combination · converted to % from 46 Participants as posted
show 1 more result
28.1% (n=121) @ 87wk*
First adjudicated clinical failure event
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 34 Participants as posted
All-cause Mortality 3.6% (n=253) @ 87wk
absolute value · percentage points
No placebo or comparator arm
Death (all-cause)
NCT01178073 · Phase 3 · registry result, not featured evidence · combination · converted to % from 9 Participants as posted
show 1 more result
5% (n=121) @ 87wk*
Death (all-cause)
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 6 Participants as posted
Disease Progression Event 4% (n=253) @ 87wk
event count · % of participants
No placebo or comparator arm
Disease progression
NCT01178073 · Phase 3 · registry result, not featured evidence · combination · converted to % from 10 Participants as posted
show 1 more result
3.3% (n=121) @ 87wk*
Disease progression
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 4 Participants as posted
NT-Pro BNP -67.15% (n=204) @ 24wk
percent change · % of baseline
No placebo or comparator arm
NCT01178073 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
-43.83% (n=100) @ 24wk
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy
Satisfactory Clinical 39% (n=234) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT01178073 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
27% (n=113) @ 24wk
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy
WHO Functional Class 0 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT01178073 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
0 score @ 24wk
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy
Borg Dyspnea -1 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT01178073 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
-0.5 score @ 24wk
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy

+ 1 further endpoint in the CSV export.

Available safety results

Tadalafil

Dropout rate
18%40 mg
NCT00549302 · Phase 3
show 7 more results
4%
NCT01042158 · Phase 4 · registry result, not featured evidence · combination
20.5%Combination Therapy: Ambrisentan +
NCT01178073 · Phase 3 · registry result, not featured evidence · combination
30.5%Tadalafil Monotherapy
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy
0%Heavy Weight: ≥40 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
0%Light Weight <25 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
—Light Weight: <25 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
0%Middle Weight: 25 kg to <40 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
5.4%40 mg
NCT00549302 · Phase 3
show 7 more results
—
NCT01042158 · Phase 4 · registry result, not featured evidence · combination
11.3%Combination Therapy: Ambrisentan +
NCT01178073 · Phase 3 · registry result, not featured evidence · combination
15.9%Tadalafil Monotherapy
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy
—Heavy Weight: ≥40 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
—Light Weight <25 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
—Light Weight: <25 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
—Middle Weight: 25 kg to <40 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
Serious AEs
—40 mg
NCT00549302 · Phase 3
show 7 more results
12.5%
NCT01042158 · Phase 4 · registry result, not featured evidence · combination
41.1%Combination Therapy: Ambrisentan +
NCT01178073 · Phase 3 · registry result, not featured evidence · combination
45%Tadalafil Monotherapy
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy
50%Heavy Weight: ≥40 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
—Light Weight <25 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
16.7%Light Weight: <25 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
57.1%Middle Weight: 25 kg to <40 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
oedema peripheral 44%
headache 41.1%
diarrhoea 20.9%
NCT01178073 · Phase 3 · registry result, not featured evidence · combination
show 4 more results
headache 36.4%
oedema peripheral 29.1%
dyspnoea 18.5%
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy
angina pectoris 33.3%
ear pain 33.3%
headache 33.3%
NCT01484431 · Phase 1/2 · registry result, not featured evidence
gastroenteritis 50%
bronchitis 33.3%
ecchymosis 33.3%
NCT01484431 · Phase 1/2 · registry result, not featured evidence
oropharyngeal pain 42.9%
headache 28.6%
pain in extremity 28.6%
NCT01484431 · Phase 1/2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Tadalafil's landscape · Udenafil's landscape